Drug Trial Radar · NCT07830719
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 18, 2026
Primary completion
Aug 15, 2027
Study completion Aug 15, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)
Conditions
- Coronary Artery Disease
Interventions
YMI024Drug
YMI024 in different doses
PlaceboDrug
matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in log-transformed IL-6Time frame: Baseline and approximately 3 months
Locations
23 sites in 5 countries. Site status is shown where the registry gives one.
Eastern Shore Research Institute
Fairhope, Alabama · Recruiting
G and L Research LLC
Foley, Alabama · Recruiting
Biopharma Informatic LLC
Los Angeles, California · Recruiting
AMR Miami
Coral Gables, Florida · Recruiting
Alliance for Multispecialty Research
Wichita, Kansas · Recruiting
Anderson Medical Research
Ft. Washington, Maryland · Recruiting
MD Medical Research
Oxon Hill, Maryland · Recruiting
Pharma Tex Research
Amarillo, Texas · Recruiting
Selma Medical Associates
Winchester, Virginia · Recruiting
Novartis Investigative Site
Adelaide, South Australia, Australia · Recruiting
Novartis Investigative Site
Frankston, Victoria, Australia · Recruiting
Novartis Investigative Site
Melbourne, Victoria, Australia · Recruiting
Novartis Investigative Site
Mulgrave, Victoria, Australia · Recruiting
Novartis Investigative Site
Berlin, Germany · Recruiting
Novartis Investigative Site
Mannheim, Germany · Recruiting
Novartis Investigative Site
Pirna, Germany · Recruiting
Novartis Investigative Site
Stuttgart, Baden-Wurttemberg, Germany · Recruiting
Novartis Investigative Site
Kaiserslautern, Rhineland-Palatinate, Germany · Recruiting
Novartis Investigative Site
Kasugai, Aichi-ken, Japan · Recruiting
Novartis Investigative Site
Matsudo, Chiba, Japan · Recruiting
Novartis Investigative Site
Kamakura, Kanagawa, Japan · Recruiting
Novartis Investigative Site
Matsubara, Osaka, Japan · Recruiting
Novartis Investigative Site
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.